Sulphasalazine, a combination of sulphapyridine and 5-aminosalicylic acid, has recently been shown to be an effective second line agent in the treatment of rheumatoid arthritis. 20 patients were treated for 12 weeks either with sulphasalazine or 5-aminosalicylic acid (5-ASA) to investigate whether 5-ASA is the active moiety. In a second investigation the analgesic effect of 5-ASA was studied. 5-ASA showed no second line effect and no analgesic effect. Sulphapyridine therefore appears to be the active moiety.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Monitoring for 5-aminosalicylate nephrotoxicity in adults with inflammatory bowel disease: prognostic model development and validation using data from the Clinical Practice Research Datalink.
BMJ Open Gastroenterol
January 2025
Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Objective: To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.
Methods: This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019.
Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis.
Adv Ther
January 2025
Bristol Myers Squibb, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
Introduction: This retrospective claims analysis characterized contemporary ulcerative colitis (UC) treatment patterns and investigated the economic burden of UC in Japan.
Methods: This study used anonymized claims data in the Medical Data Vision database. Patients were included if they had a confirmed UC diagnosis and ≥ 1 claim of systemic treatment for UC (index date) between June 2018 and December 2022, in addition to continuous enrollment for ≥ 6 months before and ≥ 12 months after the index date.
Protective effect of low-dose lactulose in dextran sulfate sodium induced ulcerative colitis model of rats.
Sci Rep
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, No.137 LiYuShan Road Xinjiang Province, Urumqi, 830000, China.
Although low-dose lactulose has shown a good theoretical foundation for the treatment of ulcerative colitis (UC) in previous studies, the exact effects and mechanism remain unclear. The rats were randomly distributed into 5 groups, i.e.
View Article and Find Full Text PDFSuccessful Treatment of Refractory Ulcerative Colitis With 5-Aminosalicylic Acid Intolerance and Biologic Therapy Resistance Using Combined Granulocyte and Monocyte Adsorptive Apheresis.
Cureus
January 2025
Department of Gastroenterology, Tsuchiya General Hospital, Hiroshima, JPN.
We report the case of a 37-year-old male patient diagnosed with moderate left-sided ulcerative colitis (UC). Initial therapy with 5-aminosalicylic acid (5-ASA) was terminated within days due to exacerbation of symptoms, leading to a diagnosis of 5-ASA intolerance. Although induction of remission was achieved with prednisolone, the patient developed steroid dependency.
View Article and Find Full Text PDFClinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.
Eur J Med Res
January 2025
Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university), 120 Heping Road, Yuhu District, Xiangtan, 411100, Hunan, China.
Background: Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab.
Methods: We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!